Jihad Inshasi

1.1k total citations
68 papers, 715 citations indexed

About

Jihad Inshasi is a scholar working on Pathology and Forensic Medicine, Neurology and Rheumatology. According to data from OpenAlex, Jihad Inshasi has authored 68 papers receiving a total of 715 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Pathology and Forensic Medicine, 27 papers in Neurology and 16 papers in Rheumatology. Recurrent topics in Jihad Inshasi's work include Multiple Sclerosis Research Studies (44 papers), Peripheral Neuropathies and Disorders (15 papers) and Rheumatoid Arthritis Research and Therapies (10 papers). Jihad Inshasi is often cited by papers focused on Multiple Sclerosis Research Studies (44 papers), Peripheral Neuropathies and Disorders (15 papers) and Rheumatoid Arthritis Research and Therapies (10 papers). Jihad Inshasi collaborates with scholars based in United Arab Emirates, Kuwait and Qatar. Jihad Inshasi's co-authors include Saeed Bohlega, Raed Alroughani, Maurice Dahdaleh, Bassem Yamout, Magd Zakaria, Peter Rieckmann, Mohammad Ali Sahraian, Dirk Deleu, Taoufik Alsaadi and Mohammed Aljumah and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Scientific Reports.

In The Last Decade

Jihad Inshasi

57 papers receiving 695 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jihad Inshasi United Arab Emirates 15 483 179 135 118 106 68 715
Jasem Al–Hashel Kuwait 20 587 1.2× 214 1.2× 122 0.9× 58 0.5× 159 1.5× 67 872
Maria Lopez-Bresnahan United States 13 418 0.9× 214 1.2× 121 0.9× 82 0.7× 93 0.9× 15 692
Liliana Patrucco Argentina 17 687 1.4× 269 1.5× 98 0.7× 142 1.2× 207 2.0× 83 992
Brandon Beaber United States 8 458 0.9× 115 0.6× 57 0.4× 99 0.8× 101 1.0× 12 640
Juha-Pekka Erälinna Finland 14 406 0.8× 161 0.9× 154 1.1× 102 0.9× 195 1.8× 24 748
Pål Berg‐Hansen Norway 16 475 1.0× 148 0.8× 70 0.5× 45 0.4× 117 1.1× 40 699
Augusto Miravalle United States 10 412 0.9× 155 0.9× 208 1.5× 42 0.4× 47 0.4× 28 629
Christina Caon United States 20 783 1.6× 381 2.1× 220 1.6× 41 0.3× 211 2.0× 36 1.0k
Jolijn J Kragt Netherlands 12 382 0.8× 118 0.7× 64 0.5× 39 0.3× 155 1.5× 15 541
Salim Chahin United States 14 339 0.7× 158 0.9× 65 0.5× 43 0.4× 68 0.6× 28 460

Countries citing papers authored by Jihad Inshasi

Since Specialization
Citations

This map shows the geographic impact of Jihad Inshasi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jihad Inshasi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jihad Inshasi more than expected).

Fields of papers citing papers by Jihad Inshasi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jihad Inshasi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jihad Inshasi. The network helps show where Jihad Inshasi may publish in the future.

Co-authorship network of co-authors of Jihad Inshasi

This figure shows the co-authorship network connecting the top 25 collaborators of Jihad Inshasi. A scholar is included among the top collaborators of Jihad Inshasi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jihad Inshasi. Jihad Inshasi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Inshasi, Jihad, et al.. (2024). MOGAD and NMOSD: insights on patients’ radiological and laboratory findings from a single UAE center. Frontiers in Neurology. 15. 1480723–1480723.
2.
Zeineddine, Maya, Raed Alroughani, Samar Farouk Ahmed, et al.. (2024). Safety and effectiveness of disease-modifying therapies after switching from natalizumab. Multiple Sclerosis Journal. 30(8). 1026–1035. 2 indexed citations
3.
Jacob, Anu, et al.. (2024). Disease modifying treatment guidelines for multiple sclerosis in the United Arab Emirates. Multiple Sclerosis and Related Disorders. 88. 105703–105703.
4.
5.
Inshasi, Jihad, Ali Hassan, Miklós Szólics, et al.. (2023). Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study. Neurology and Therapy. 12(4). 1309–1318. 5 indexed citations
6.
Sharmin, Sifat, Charles B. Malpas, Vahid Shaygannejad, et al.. (2022). External validation of a clinical prediction model in multiple sclerosis. Multiple Sclerosis Journal. 29(2). 261–269. 1 indexed citations
7.
Alroughani, Raed, Jihad Inshasi, Samar Farouk Ahmed, et al.. (2022). Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review. Multiple Sclerosis Journal - Experimental Translational and Clinical. 8(1). 3090440385–3090440385. 3 indexed citations
8.
Alroughani, Raed, et al.. (2022). Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East. Journal of Clinical Neuroscience. 99. 311–316. 4 indexed citations
9.
10.
Alroughani, Raed, Ahmed Ali Hassan, Naji Riachi, et al.. (2021). Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA). Clinical Neurology and Neurosurgery. 203. 106576–106576. 3 indexed citations
11.
Yamout, Bassem, Mohammad Ali Sahraian, Saeed Bohlega, et al.. (2019). Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Multiple Sclerosis and Related Disorders. 37. 101459–101459. 75 indexed citations
12.
Qidwai, Uvais, et al.. (2019). Adaptive Neuro-Fuzzy Inference System for Prediction of Surgery Time for Ischemic Stroke Patients. International Journal of Integrated Engineering. 11(3). 4 indexed citations
13.
Alroughani, Raed, et al.. (2019). An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion. Neurology and Therapy. 8(1). 13–23. 22 indexed citations
14.
15.
Kamran, Saadat, Abdul Salam, Naveed Akhtar, et al.. (2017). Predictors of In-Hospital Mortality after Decompressive Hemicraniectomy for Malignant Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases. 26(9). 1941–1947. 10 indexed citations
16.
Coles, Alasdair, Alexey Boyко, J. A. Cohen, et al.. (2016). Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I).. Multiple Sclerosis Journal. 22. 75–76. 7 indexed citations
17.
Karabudak, Rana, Maurice Dahdaleh, Mohammed Aljumah, et al.. (2015). Functional clinical outcomes in multiple sclerosis: Current status and future prospects. Multiple Sclerosis and Related Disorders. 4(3). 192–201. 27 indexed citations
18.
Bohlega, Saeed, et al.. (2013). Multiple sclerosis in the Arabian Gulf countries: a consensus statement. Journal of Neurology. 260(12). 2959–2963. 63 indexed citations
19.
Saadah, Mohammed Ahmed, et al.. (2004). Atypical presentations of conus medullaris and filum terminale myxopapillary ependymomas. Journal of Clinical Neuroscience. 11(3). 268–272. 11 indexed citations
20.
Saadah, Mohammed Ahmed, et al.. (2002). Pilomotor seizures: symptomatic vs. idiopathic report of two cases and literature review. Seizure. 11(7). 455–459. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jasem Al–Hashel Breakdown of academic impact, for papers by Maria Lopez-Bresnahan Breakdown of academic impact, for papers by Liliana Patrucco Breakdown of academic impact, for papers by Brandon Beaber Breakdown of academic impact, for papers by Juha-Pekka Erälinna Breakdown of academic impact, for papers by Pål Berg‐Hansen Breakdown of academic impact, for papers by Augusto Miravalle Breakdown of academic impact, for papers by Christina Caon Breakdown of academic impact, for papers by Jolijn J Kragt Breakdown of academic impact, for papers by Salim Chahin
Rankless by CCL
2026